DNA damaging agents in combination with tyrosine kinase inhibitors
View Patent ↗Methods and compositions for enhancing cancer cell death using therapeutically effective amounts of DNA damaging agent(s) that act in combination to enhance cancer cell death, e.g., nucleic acid precursors, and protein tyrosine kinase inhibitors, e.g., that inhibit EGFR activity. The agents and inhibitors are administered in an amount effective to kill cancer cells, that is, the combined effect is sufficient so that cancer cell death is enhanced. If not administered at the same time, the DNA damaging agent(s) and tyrosine kinase inhibitors are administered close enough in time so they are still able to enhance cancer cell death. The methods and compositions are useful to treat neoplastic disease, e.g., pancreatic cancer.
1. A method of improving chemotherapeutic intervention in a patient, the method comprising:
(a) administering a DNA damaging agent to the patient;
(b) administering a therapeutically effective amount of a low molecular weight tyrosine kinase inhibitor to the patient, wherein the low molecular weight inhibitor binds intracellularly to inhibit the activity of more than one tyrosine kinase protein, and wherein the agent and the inhibitor act in combination by effecting a series of intracellular events to enhance cell death, thereby improving chemotherapeutic intervention.
2. A method of improving chemotherapeutic intervention in a patient, the method comprising:
(a) administering a DNA damaging agent to the patient; and
(b) administering a therapeutically effective amount of a low molecular weight tyrosine kinase inhibitor to the patient, wherein the low molecular weight inhibitor binds intracellularly to inhibit the activity of more than one tyrosine kinase protein and intracellularly inhibits phosphorylation of downstream effector molecules, and wherein the agent and the inhibitor act in combination to enhance cell death, thereby improving chemotherapeutic intervention.
3. A method of improving chemotherapeutic intervention in a patient, the method comprising:
(a) administering a DNA damaging agent to the patient;
(b) administering a therapeutically effective amount of a low molecular weight tyrosine kinase inhibitor to the patient, wherein the low molecular weight inhibitor binds intracellularly to inhibit the activity of EGFR and at least one other tyrosine kinase protein by intracellularly inhibiting phosphorylation of downstream effector molecules, and wherein the agent and the inhibitor act in combination to enhance cell death, thereby improving chemotherapeutic intervention.
4. A method of improving chemotherapeutic intervention in a patient, the method comprising:
(a) administering a DNA damaging agent to the patient;
(b) administering a therapeutically effective amount of a low molecular weight tyrosine kinase inhibitor to the patient, wherein the low molecular weight inhibitor binds intracellularly to inhibit the activity of EGFR and at least one other tyrosine kinase protein by intracellularly inhibiting the phosphorylation of downstream effector molecules to prevent DNA repair during G2 arrest, and wherein the agent and the inhibitor act in combination to enhance cell death, thereby improving chemotherapeutic intervention.
5. A method of enhancing apoptosis of cancer cells in a patient comprising chemotherapeutic intervention in a patient, the method comprising:
(a) administering a DNA damaging agent to the patient;
(b) administering a therapeutically effective amount of a low molecular weight tyrosine kinase inhibitor to the patient, wherein the low molecular weight inhibitor binds intracellularly to inhibit the activity of more than one tyrosine kinase protein and intracellularly inhibits phosphorylation of downstream effector molecules, and wherein the agent and the inhibitor act in combination to enhance apoptosis.
6. A method of improving chemotherapeutic intervention in a patient, the method comprising:
(a) administering a DNA damaging agent to the patient;
(b) administering a therapeutically effective amount of a low molecular weight tyrosine kinase inhibitor to the patient, wherein the low molecular weight inhibitor binds intracellularly to alter substrate function by inhibiting substrate phosphorylation, and wherein the agent and the inhibitor act in combination to alter the cell's response to the agent, thereby improving chemotherapeutic intervention.
7. A method of improving chemotherapeutic intervention in a patient, the method comprising:
(a) administering a DNA damaging agent to the patient;
(b) administering a therapeutically effective amount of a low molecular weight tyrosine kinase inhibitor to the patient, wherein the low molecular weight inhibitor binds intracellularly to inhibit the activity of more than one tyrosine kinase protein to prevent DNA repair during G2 arrest, and wherein the agent and the inhibitor act in combination to enhance cell death, thereby improving chemotherapeutic intervention.